Boston Scientific Eluvia drug-eluting stent demonstrates superior results
Boston Scientific announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery. In the IMPERIAL trial, the Eluvia stent exhibited superior rates of primary patency. September 22, 2018